Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease
Phase of Trial: Phase IV
Latest Information Update: 11 May 2018
Price : $35 *
At a glance
- Drugs Eplerenone (Primary)
- Indications Heart disorders
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Dec 2014 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.